642 related articles for article (PubMed ID: 34312554)
41. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
42. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR; Belij-Rammerstorfer S; Dold C; Ewer KJ; Folegatti PM; Gilbride C; Halkerston R; Hill J; Jenkin D; Stockdale L; Verheul MK; Aley PK; Angus B; Bellamy D; Berrie E; Bibi S; Bittaye M; Carroll MW; Cavell B; Clutterbuck EA; Edwards N; Flaxman A; Fuskova M; Gorringe A; Hallis B; Kerridge S; Lawrie AM; Linder A; Liu X; Madhavan M; Makinson R; Mellors J; Minassian A; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Rollier CS; Song R; Snape MD; Tarrant R; Taylor S; Thomas KM; Voysey M; Watson MEE; Wright D; Douglas AD; Green CM; Hill AVS; Lambe T; Gilbert S; Pollard AJ;
Nat Med; 2021 Feb; 27(2):279-288. PubMed ID: 33335322
[TBL] [Abstract][Full Text] [Related]
43. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
Front Immunol; 2021; 12():727850. PubMed ID: 34671350
[TBL] [Abstract][Full Text] [Related]
44. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Corbett KS; Nason MC; Flach B; Gagne M; O'Connell S; Johnston TS; Shah SN; Edara VV; Floyd K; Lai L; McDanal C; Francica JR; Flynn B; Wu K; Choi A; Koch M; Abiona OM; Werner AP; Moliva JI; Andrew SF; Donaldson MM; Fintzi J; Flebbe DR; Lamb E; Noe AT; Nurmukhambetova ST; Provost SJ; Cook A; Dodson A; Faudree A; Greenhouse J; Kar S; Pessaint L; Porto M; Steingrebe K; Valentin D; Zouantcha S; Bock KW; Minai M; Nagata BM; van de Wetering R; Boyoglu-Barnum S; Leung K; Shi W; Yang ES; Zhang Y; Todd JM; Wang L; Alvarado GS; Andersen H; Foulds KE; Edwards DK; Mascola JR; Moore IN; Lewis MG; Carfi A; Montefiori D; Suthar MS; McDermott A; Roederer M; Sullivan NJ; Douek DC; Graham BS; Seder RA
Science; 2021 Sep; 373(6561):eabj0299. PubMed ID: 34529476
[TBL] [Abstract][Full Text] [Related]
45. Rapid and stable mobilization of CD8
Oberhardt V; Luxenburger H; Kemming J; Schulien I; Ciminski K; Giese S; Csernalabics B; Lang-Meli J; Janowska I; Staniek J; Wild K; Basho K; Marinescu MS; Fuchs J; Topfstedt F; Janda A; Sogukpinar O; Hilger H; Stete K; Emmerich F; Bengsch B; Waller CF; Rieg S; Sagar ; Boettler T; Zoldan K; Kochs G; Schwemmle M; Rizzi M; Thimme R; Neumann-Haefelin C; Hofmann M
Nature; 2021 Sep; 597(7875):268-273. PubMed ID: 34320609
[TBL] [Abstract][Full Text] [Related]
46. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
[No Abstract] [Full Text] [Related]
47. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
Kang CM; Lee NY; Lin CH; Hsu YS; Chang YC; Chung MY; Lee YF; Tseng WP; Wu JL; Chen SY; Lu MC; Ko WC; Lee PI; Hsueh PR
J Clin Virol; 2022 Jun; 150-151():105156. PubMed ID: 35413588
[TBL] [Abstract][Full Text] [Related]
48. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.
Nguyen TT; Quach THT; Tran TM; Phuoc HN; Nguyen HT; Vo TK; Vo GV
Biomed Pharmacother; 2022 Mar; 147():112650. PubMed ID: 35066301
[TBL] [Abstract][Full Text] [Related]
49. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
Luo S; Zhang P; Liu B; Yang C; Liang C; Wang Q; Zhang L; Tang X; Li J; Hou S; Zeng J; Fu Y; Allain JP; Li T; Zhang Y; Li C
Emerg Microbes Infect; 2021 Dec; 10(1):1002-1015. PubMed ID: 33993845
[No Abstract] [Full Text] [Related]
50. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
51. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
52. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Immunol; 2021; 12():779212. PubMed ID: 34899739
[TBL] [Abstract][Full Text] [Related]
53. Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant.
Pastore G; Polvere J; Fiorino F; Lucchesi S; Montesi G; Rancan I; Zirpoli S; Lippi A; Durante M; Fabbiani M; Tumbarello M; Montagnani F; Medaglini D; Ciabattini A
Expert Rev Vaccines; 2024; 23(1):432-444. PubMed ID: 38517153
[TBL] [Abstract][Full Text] [Related]
54. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Bradley T; Grundberg E; Selvarangan R; LeMaster C; Fraley E; Banerjee D; Belden B; Louiselle D; Nolte N; Biswell R; Pastinen T; Myers A; Schuster J
N Engl J Med; 2021 May; 384(20):1959-1961. PubMed ID: 33755375
[No Abstract] [Full Text] [Related]
55. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.
Bánki Z; Mateus J; Rössler A; Schäfer H; Bante D; Riepler L; Grifoni A; Sette A; Simon V; Falkensammer B; Ulmer H; Neurauter B; Borena W; ; Krammer F; von Laer D; Weiskopf D; Kimpel J
EBioMedicine; 2022 Jun; 80():104073. PubMed ID: 35617826
[TBL] [Abstract][Full Text] [Related]
56. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
57. Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine.
Yang J; Ko JH; Baek JY; Hong J; Ha S; Lee B; Huh K; Cho SY; Kang CI; Chung DR; Kim YJ; Kang ES; Peck KR
Front Immunol; 2021; 12():744206. PubMed ID: 34630425
[TBL] [Abstract][Full Text] [Related]
58. Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4
Meyer-Arndt L; Schwarz T; Loyal L; Henze L; Kruse B; Dingeldey M; Gürcan K; Uyar-Aydin Z; Müller MA; Drosten C; Paul F; Sander LE; Demuth I; Lauster R; Giesecke-Thiel C; Braun J; Corman VM; Thiel A
J Immunol; 2022 Mar; 208(5):1001-1005. PubMed ID: 35121642
[TBL] [Abstract][Full Text] [Related]
59. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
[TBL] [Abstract][Full Text] [Related]
60. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
Pascuale CA; Varese A; Ojeda DS; Pasinovich ME; Lopez L; Rossi AH; Rodriguez PE; Miglietta EA; ; Mazzitelli I; Di Diego Garcia F; Sanchez L; Rouco SO; Gonzalez Lopez Ledesma MM; Zurano JP; Mazzitelli B; Scruzzi G; Barbero P; Cardozo D; Gallego S; Borda M; Diaz M; ; ; Ridao F; Rosales AB; ; Bhon J; Talia JM; Diangelo ME; Lacaze MA; ; Aime B; Gutierrez SI; Ercole R; Toro R; Tau L; Delaplace L; Compagnucci MF; ; Sartori C; Desimone I; Echegoyen C; Velazquez P; Testa C; ; Hozbor D; Docena G; Laino CH; Kreplak N; Pifano M; Barbas G; Rearte A; Vizzotti C; Castelli JM; Geffner J; Gamarnik AV
Cell Rep Med; 2022 Aug; 3(8):100706. PubMed ID: 35926505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
